The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAFV600-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERINGMELANOMA.
 
Erika Richtig
Honoraria - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp Dohme; Novartis; Pierre Fabre; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bayer; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre
Speakers' Bureau - Amgen; Bristol-Myers Squibb; Merck; Merck; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Merck; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche; Sanofi
 
Ralf Gutzmer
Honoraria - Almirall Hermal GmbH; Amgen; Bayer; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron; Sun Pharma
Consulting or Advisory Role - 4SC; Almirall Hermal GmbH; Amgen; Bristol-Myers Squibb; Immunocore; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi; Sun Pharma
Research Funding - Amgen (Inst); Johnson & Johnson (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Sun Pharma (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Pierre Fabre; Roche; Sun Pharma
 
Carmen Loquai
Consulting or Advisory Role - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Kyowa Kirin; Merck; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma
Speakers' Bureau - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Kyowa Kirin; Merck; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma
Travel, Accommodations, Expenses - Almirall Hermal GmbH; BioNTech; Bristol-Myers Squibb; Kyowa Kirin; Merck; MSD; Novartis; Pierre Fabre; Roche; Sun Pharma
 
Jochen Utikal
Stock and Other Ownership Interests - BioNTech; Moderna Therapeutics; Pfizer; Sanofi
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi
Research Funding - Apogenix (Inst); Merck (Inst); Noxxon Pharma (Inst)
Travel, Accommodations, Expenses - Pierre Fabre; Sanofi
 
Christoph Hoeller
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Sanofi
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
 
Rudolf Stadler
Honoraria - 4SC; Merck; Takeda
Consulting or Advisory Role - Takeda
 
Andrea Forschner
Honoraria - Bristol-Myers Squibb; CeGaT; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche
Research Funding - Stiftung Immunonkologie BMS (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pierre Fabre; Roche
 
Jessica Cecile Hassel
Honoraria - Almirall Hermal GmbH; Bristol Myers Squibb Foundation; MSD; Novartis; Roche Pharma AG; Sanofi; Sun Pharma
Consulting or Advisory Role - Sanofi Aventis GmbH; Sun Pharma
Research Funding - 4SC (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Idera (Inst); Immunocore (Inst); Novartis (Inst); Philogen (Inst)
 
Daniela Goeppner
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pierre Fabre; Sanofi
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis; Pierre Fabre; Sanofi
 
Michael Fluck
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche; Sanofi
 
Sebastian Haferkamp
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst)
 
Martin Kaatz
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Federal Ministry of Education and Research (Inst)
Expert Testimony - Novartis; Roche
 
Manfred Welslau
Honoraria - Amgen; Astellas Pharma; AstraZeneca; Celgene; Hexal; Janssen; Lilly; Novartis; Roche; Sanofi
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Hexal; Janssen; Lilly; Medac; Novartis; Roche; Sanofi
 
Reinhard Dummer
Honoraria - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Consulting or Advisory Role - Alligator Bioscience; Amgen; Bristol-Myers Squibb; Catalym; MaxiVax; MSD; Novartis; Pierre Fabre; Regeneron; Roche; Sanofi; Second Genome; Sun Pharma; Takeda; touchIME
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); MSD (Inst); Novartis (Inst); Roche (Inst)
 
Roger Anton Fredy Von Moos
Honoraria - AstraZeneca (Inst); Bayer/Onyx; Roche
Consulting or Advisory Role - Amgen (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Roche (Inst); Roche/Genentech (Inst); Tesaro
Research Funding - Bayer/Onyx (Inst); Merck Serono (Inst)
Travel, Accommodations, Expenses - Pfizer
Other Relationship - Pfizer
 
Andrea Schmidt
Travel, Accommodations, Expenses - Alcedis
Other Relationship - Alcedis
 
Laura Milde
Employment - Pierre Fabre
Stock and Other Ownership Interests - Pierre Fabre
 
Olivier Michielin
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; MSD; NeraCare GmbH
Expert Testimony - Bristol-Myers Squibb
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD
 
Dirk Schadendorf
Honoraria - 4SC; Array BioPharma; Bristol-Myers Squibb; Immunocore; InflarxGmbH; Merck Serono; Merck Sharp & Dohme; NeraCare GmbH; Novartis; Pfizer; Philogen; Pierre Fabre; Regeneron; Roche/Genentech; Sandoz; Sanofi/Regeneron; Sun Pharma; Ultimovacs
Consulting or Advisory Role - 4SC; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; NEKTAR; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron
Speakers' Bureau - Bristol-Myers Squibb; Merck KGaA; Merck Sharp & Dohme; Novartis; Pierre Fabre; Sanofi/Regeneron
Research Funding - Array BioPharma/Pfizer (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche/Genentech; Sanofi/Regeneron